Evidence Hub

MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review

F. J. Bolte, C. Luminais, M. Mistro, M. Devitt

Case Reports in Oncology, 2025

1 citation

Abstract

Abstract Introduction: Metastasis-directed therapy is an evolving treatment modality for patients with oligometastatic prostate cancer. Although the microenvironment of the adrenal glands is enriched in androgen precursors, isolated adrenal metastases are rare. The application of stereotactic ablative radiotherapy (SBRT) to oligometastatic adrenal lesions has been limited due to toxicity concerns. Case Presentation: We report a patient with castration resistant prostate cancer and oligometastatic disease recurrence to the adrenal gland who underwent MRI-guided adaptive radiotherapy, which allowed accurate delivery of SBRT while minimizing exposure to adjacent radiosensitive organs. This approach was safe and resulted in long-term local and systemic disease control. Conclusion: This case highlights the potential role for MRI-guided SBRT in selected patients with oligometastatic prostate cancer to the adrenal glands.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free